PALI PALISADE BIO INC

Palisade Bio Selected for Poster Presentation at the 2025 Crohn’s & Colitis Congress

Palisade Bio Selected for Poster Presentation at the 2025 Crohn’s & Colitis Congress

Carlsbad, CA, Jan. 29, 2025 (GLOBE NEWSWIRE) --  (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that its abstract has been accepted for poster presentation at the being held February 6-8, 2025 in San Francisco, CA.

Details of the poster presentation are as follows:

Session: Poster and Exhibition Hall Reception

Poster Title: PALI-2108, a Colon-Specific PDE4B Inhibitor Prodrug is Activated in the Colon and Reduces Ulcerative Colitis Symptoms in an Acute Colitis DSS Mouse Model

Session Dates and Times: February 7, 2025 from 5:00 PM to 6:30 PM PST

Presentation Location: Level 1 – Exhibition Hall – Moscone West

For more information about the congress, please visit .

About Palisade Bio 

Palisade Bio is a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company believes that by using a targeted approach with its novel therapeutics it will transform the treatment landscape. For more information, please go to .

Investor Relations Contact

JTC Team, LLC

Jenene Thomas

908-824-0775



EN
29/01/2025

Underlying

PALIPALISADE BIO INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on PALISADE BIO INC

 PRESS RELEASE
Free
PALI PALISADE BIO IN...

Palisade Bio Announces Exercise of Previously Issued Warrants for $3.9...

Palisade Bio Announces Exercise of Previously Issued Warrants for $3.9 Million Carlsbad, CA, July 23, 2025 (GLOBE NEWSWIRE) --  (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced an agreement between the Company and several accredited investors to exercise certain existing warrants (the “Existing Warrants”) to purchase up to an aggregate of 4,318,905 shares of common stock. The Existing Warrants had adjusted ...

July 24, 2025 1 EN
 PRESS RELEASE
Free
PALI PALISADE BIO IN...

Palisade Bio Participates in the Virtual Investor “What’s Your Story” ...

Palisade Bio Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference – Video webcast now available on-demand Carlsbad, CA, July 22, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced  of Palisade Bio, participated in the . As part of the event, Mr. Finley dove deeper into his dedication to the Company, how he...

July 22, 2025 1 EN
 PRESS RELEASE
Free
PALI PALISADE BIO IN...

Palisade Bio Appoints Emil Chuang, MB BS FRACP to its Board of Directo...

Palisade Bio Appoints Emil Chuang, MB BS FRACP to its Board of Directors Veteran clinical leader with successful track record and experience to help guide the Company’s clinical strategy in Fibrostenotic Crohn’s Disease and Ulcerative Colitis Carlsbad, CA, July 09, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced it has appointed Emil Chuang, MB BS FRACP to its Board of D...

July 9, 2025 1 EN
 PRESS RELEASE
Free
PALI PALISADE BIO IN...

Palisade Bio Reports Positive Phase 1a Results for PALI-2108, a First-...

Palisade Bio Reports Positive Phase 1a Results for PALI-2108, a First-in-Class Terminal Ileum and Colon-Targeted PDE4 B/D Inhibitor for Fibrostenotic Crohn’s Disease and Ulcerative Colitis Study met its primary endpoints of safety, tolerability, and pharmacokinetics (PK)  No serious adverse events (SAEs) or treatment-emergent adverse events (TEAEs) related to laboratory values or EKGs observed across SAD/MAD cohorts Management releases a “What This Means” segment discussing the topline Phase 1a data; Carlsbad, CA, May 27, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Pa...

May 27, 2025 1 EN
 PRESS RELEASE
Free
PALI PALISADE BIO IN...

Palisade Bio Presents Positive Preclinical Data Highlighting Potential...

Palisade Bio Presents Positive Preclinical Data Highlighting Potential of PALI-2108 as a Promising Colon-Specific PDE4 Inhibitor for the Treatment of Ulcerative Colitis and Other Inflammatory Bowel Diseases Two posters presented at Digestive Disease Week (DDW) 2025 Preclinical results indicate that PALI-2108 effectively modulates inflammatory pathways in the colon, promoting a favorable immune response Company advancing Phase 1a/b study of PALI-2108 and has demonstrated a favorable safety profile in single-ascending-dose cohorts Carlsbad, CA, May 06, 2025 (GLOBE NEWSWIRE) -- Palisade B...

May 6, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch